Piotrowska, Zofia

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 985

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 665

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 583

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 216

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 95

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS -Mutant Non–Small Cell Lung Cancer

Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery

Cell death mechanisms and regulationLung Cancer Treatments and Mutations

Cited by 94

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Piotrowska, Z., Costa, D. B., Oxnard, G. R., Huberman, M., Gainor, J. F., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., Heist, R. S., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 79

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., Costa, D., Zhang, S., Bottino, D., Zhu, J., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 28

Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC

Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 14